A61K 47/22
Heterocyclic compounds
Official title: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K47/22 (Heterocyclic compounds) appears on 2,684 US grants and 4,951 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,684
- Published applications
- 4,951
- Assignees
- 1,972
- Inventors
- 8,268
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 7 | 0 |
| 1978 | 7 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 4 | 0 |
| 1982 | 2 | 0 |
| 1983 | 11 | 0 |
| 1984 | 9 | 0 |
| 1985 | 8 | 0 |
| 1986 | 5 | 0 |
| 1987 | 8 | 0 |
| 1988 | 15 | 0 |
| 1989 | 20 | 0 |
| 1990 | 14 | 0 |
| 1991 | 20 | 0 |
| 1992 | 12 | 0 |
| 1993 | 19 | 0 |
| 1994 | 12 | 0 |
| 1995 | 13 | 0 |
| 1996 | 8 | 0 |
| 1997 | 11 | 0 |
| 1998 | 20 | 0 |
| 1999 | 33 | 0 |
| 2000 | 26 | 0 |
| 2001 | 20 | 10 |
| 2002 | 23 | 19 |
| 2003 | 16 | 58 |
| 2004 | 13 | 44 |
| 2005 | 14 | 56 |
| 2006 | 11 | 43 |
| 2007 | 8 | 50 |
| 2008 | 10 | 63 |
| 2009 | 16 | 71 |
| 2010 | 23 | 78 |
| 2011 | 29 | 94 |
| 2012 | 41 | 102 |
| 2013 | 64 | 176 |
| 2014 | 117 | 245 |
| 2015 | 109 | 276 |
| 2016 | 188 | 282 |
| 2017 | 179 | 280 |
| 2018 | 179 | 288 |
| 2019 | 168 | 313 |
| 2020 | 193 | 329 |
| 2021 | 168 | 361 |
| 2022 | 159 | 358 |
| 2023 | 148 | 339 |
| 2024 | 174 | 374 |
| 2025 | 195 | 338 |
| 2026 | 125 | 304 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Ketamine formulation6 Oct 2026US 12,751,918 B2Fresenius Kabi USA, LLC
- Method of treating a child with central precocious puberty using an extended release composition6 Oct 2026US 12,751,990 B2Tolmar International Limited
- Radiopharmaceutical compositions for actinium in targeted radionuclide therapy6 Oct 2026US 12,752,026 B2Curium US LLC
- Blood-brain barrier permeable heteroduplex nucleic acid29 Sep 2026US 12,746,253 B2National University Corporation Tokyo Medical and Dental University
- Pharmaceutical formulations22 Sep 2026US 12,741,013 B2Novo Nordisk A/S
- Formulation for an effective oral administration of ciclopirox with no adversal gastrointestinal toxicity8 Oct 2026US 2026/0306400 A1AsociacióN Centro De InvestigacióN Cooperativa En Biociencias-Cic Biogune
- Compositions, methods of treatment, and containers including compositions8 Oct 2026US 2026/0306427 A1
- N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof8 Oct 2026US 2026/0306454 A1
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Polymorphic forms and formulations of leriglitazone8 Oct 2026US 2026/0306468 A1Minoryx Therapeutics S.L.
Most cited
By later US patents
- Transdermal and trans-membrane delivery of drugs515US 5,023,252 AConrex Pharmaceutical Corporation · 1991
- Non-polymeric sustained release delivery system326US 5,888,533 AAtrix Laboratories, Inc. · 1999
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Non-polymeric sustained release delivery system308US 5,736,152 AAtrix Laboratories, Inc. · 1998
- Human antibodies that bind human IL-12 and methods for producing300US 6,914,128 B1Abbott GmbH & Co. KG · 2005